ADGRB1抗体;ADGRB1 Antibody—艾普蒂

The ADGRB1 antibody is designed to target ADGRB1 (Adhesion G Protein-Coupled Receptor B1), also known as BAI1 (Brain-specific Angiogenesis Inhibitor 1), a member of the adhesion G protein-coupled receptor (GPCR) family. ADGRB1 is a transmembrane protein highly expressed in the brain, particularly in neurons and glial cells, and plays critical roles in cellular signaling, angiogenesis regulation, and phagocytosis of apoptotic cells. Its structure includes a large extracellular N-terminus with thrombospondin type-1 repeats, a GPCR proteolytic site (GPS) for autoproteolytic cleavage, and a seven-transmembrane domain characteristic of GPCRs. ADGRB1 is implicated in inhibiting pathological angiogenesis by interacting with integrins and modulating downstream pathways like STAT3 and p53. It also facilitates synaptic plasticity and binds phosphatidylserine on apoptotic cells to promote their clearance. Dysregulation of ADGRB1 is linked to cancers (e.g., glioblastoma), neurological disorders, and infectious diseases, as some pathogens exploit its extracellular domains for host cell entry. Antibodies against ADGRB1 are essential tools for detecting protein expression, localization, and functional studies via techniques such as Western blotting, immunohistochemistry, and immunofluorescence. They often target specific epitopes, such as the N-terminal extracellular region or C-terminal intracellular domain, enabling research into ADGRB1's dual roles in tumor suppression and neurodegenerative processes. These antibodies aid in exploring its potential as a therapeutic target or biomarker in disease contexts.